Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting
•mRNA VE against infection declined during periods of delta variant predominance.•High effectiveness of mRNA vaccines in 12–15 year old children in delta period.•Prior infection with pre-delta strains were as protective as full vaccination.•Hybrid immunity provides best protection against infection....
Gespeichert in:
| Veröffentlicht in: | Vaccine 2023-01, Vol.41 (4), p.989-998 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 998 |
|---|---|
| container_issue | 4 |
| container_start_page | 989 |
| container_title | Vaccine |
| container_volume | 41 |
| creator | Rane, Madhura S. Robertson, McKaylee M. Kulkarni, Sarah G. Frogel, Daniel Gainus, Chris Nash, Denis |
| description | •mRNA VE against infection declined during periods of delta variant predominance.•High effectiveness of mRNA vaccines in 12–15 year old children in delta period.•Prior infection with pre-delta strains were as protective as full vaccination.•Hybrid immunity provides best protection against infection.•mRNA-1273 vaccine marginally more effective compared to BNT162b2 against infection.
It is critical to monitor changes in vaccine effectiveness against COVID-19 outcomes for various vaccine products in different population subgroups.
We conducted a retrospective study in patients ≥12 years who underwent testing for SARS-CoV-2 virus from April 14 through October 25, 2021, at urgent care centers in the New York metropolitan area. Patients self-reported vaccination status at the time of testing. We used a test-negative design to estimate vaccine effectiveness (VE) by comparing odds of a positive test for SARS-CoV-2 infection among vaccinated (n = 474,805), partially vaccinated (n = 87,834), and unvaccinated (n = 369,333) patients, adjusted for demographic factors and calendar time.
VE against symptomatic infection after 2 doses of mRNA vaccine was 96% (95% Confidence Interval: 95%, 97%) in the pre-delta period and reduced to 79% (95% CI: 77%, 81%) in the delta period. In the delta period, VE for 12–15-year-olds (85%; [95% CI: 81%, 88%]) was higher compared to older age groups ( |
| doi_str_mv | 10.1016/j.vaccine.2022.12.039 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9763212</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X2201564X</els_id><sourcerecordid>2760172997</sourcerecordid><originalsourceid>FETCH-LOGICAL-c495t-bd4fdc2ae3aaf952bd319d290e04577ce0f7088438fafdffd71cc7134448e6803</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxS1ERbeFjwCyxKWXBP9LnFxA1aoFpEqVKCBultceL15t7MVOgvrt8bJLVbhwsmX_5s2beQi9pKSmhLZvNvWsjfEBakYYqymrCe-foAXtJK9YQ7unaEFYKypBybdTdJbzhhDScNo_Q6e8bbqOELlAP6-cAzP6GQLkjKPDyzh7W9EeH_Uz1mvtQx5xvh92Yxz06A3WwWL9-OHu8tNdtYxfK4Z9-C0ZQy7XQuIprSGM2OgEOMM4-rB-jk6c3mZ4cTzP0Zfrq8_LD9XN7fuPy8ubyoi-GauVFc4apoFr7fqGrWwZwLKeABGNlAaIk6TrBO-cdtY5K6kxknIhRAdtR_g5envQ3U2rAawpPpLeql3yg073Kmqv_v4J_rtax1n1suWMsiJwcRRI8ccEeVSDzwa2Wx0gTlkx2RIqWd_Lgr7-B93EKYUy3p6Sotjme0fNgTIp5pzAPZihRO2jVRt1XL3aR6soUyXaUvfq8SQPVX-yLMC7AwBln7OHpLLxEAxYn0oeykb_nxa_AM-uubQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2767429030</pqid></control><display><type>article</type><title>Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Rane, Madhura S. ; Robertson, McKaylee M. ; Kulkarni, Sarah G. ; Frogel, Daniel ; Gainus, Chris ; Nash, Denis</creator><creatorcontrib>Rane, Madhura S. ; Robertson, McKaylee M. ; Kulkarni, Sarah G. ; Frogel, Daniel ; Gainus, Chris ; Nash, Denis</creatorcontrib><description>•mRNA VE against infection declined during periods of delta variant predominance.•High effectiveness of mRNA vaccines in 12–15 year old children in delta period.•Prior infection with pre-delta strains were as protective as full vaccination.•Hybrid immunity provides best protection against infection.•mRNA-1273 vaccine marginally more effective compared to BNT162b2 against infection.
It is critical to monitor changes in vaccine effectiveness against COVID-19 outcomes for various vaccine products in different population subgroups.
We conducted a retrospective study in patients ≥12 years who underwent testing for SARS-CoV-2 virus from April 14 through October 25, 2021, at urgent care centers in the New York metropolitan area. Patients self-reported vaccination status at the time of testing. We used a test-negative design to estimate vaccine effectiveness (VE) by comparing odds of a positive test for SARS-CoV-2 infection among vaccinated (n = 474,805), partially vaccinated (n = 87,834), and unvaccinated (n = 369,333) patients, adjusted for demographic factors and calendar time.
VE against symptomatic infection after 2 doses of mRNA vaccine was 96% (95% Confidence Interval: 95%, 97%) in the pre-delta period and reduced to 79% (95% CI: 77%, 81%) in the delta period. In the delta period, VE for 12–15-year-olds (85%; [95% CI: 81%, 88%]) was higher compared to older age groups (<65% for all other age groups). VE estimates did not differ by sex and race/ethnicity. VE against symptomatic infection was the highest for individuals with a prior infection followed by full vaccination. VE against symptomatic infection after the 2-dose mRNA-1273 vaccine (82% [95% CI: 80%, 84%]) was higher compared to the BNT162b2 vaccine (76% [95% CI: 74%, 78%]) in the delta period. VE after 1-dose of the Ad26.COV2.S vaccine was the lowest compared to other vaccines (19% [95% CI: 15%, 23%]) in the delta period.
VE against infection after two doses of the mRNA vaccines was high initially, but significantly reduced against the delta variant for both FDA-approved vaccines.</description><identifier>ISSN: 0264-410X</identifier><identifier>ISSN: 1873-2518</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2022.12.039</identifier><identifier>PMID: 36588007</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>2019-nCoV Vaccine mRNA-1273 ; Ad26COVS1 ; Age groups ; Aged ; Ambulatory Care ; Antigens ; Asymptomatic ; BNT162 Vaccine ; Confidence intervals ; Coronaviruses ; COVID-19 ; COVID-19 - prevention & control ; COVID-19 diagnostic tests ; COVID-19 vaccine effectiveness ; COVID-19 Vaccines ; Disease ; Effectiveness ; Ethnicity ; Humans ; Infection-induced immunity ; Infections ; Metropolitan areas ; Mortality ; mRNA ; mRNA vaccines ; Patients ; Retrospective Studies ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Subgroups ; Test-negative design ; Vaccine efficacy ; Vaccine-induced immunity ; Vaccines ; Viral diseases</subject><ispartof>Vaccine, 2023-01, Vol.41 (4), p.989-998</ispartof><rights>2022 Elsevier Ltd</rights><rights>Copyright © 2022 Elsevier Ltd. All rights reserved.</rights><rights>2022. Elsevier Ltd</rights><rights>2022 Elsevier Ltd. All rights reserved. 2022 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c495t-bd4fdc2ae3aaf952bd319d290e04577ce0f7088438fafdffd71cc7134448e6803</citedby><cites>FETCH-LOGICAL-c495t-bd4fdc2ae3aaf952bd319d290e04577ce0f7088438fafdffd71cc7134448e6803</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X2201564X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36588007$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rane, Madhura S.</creatorcontrib><creatorcontrib>Robertson, McKaylee M.</creatorcontrib><creatorcontrib>Kulkarni, Sarah G.</creatorcontrib><creatorcontrib>Frogel, Daniel</creatorcontrib><creatorcontrib>Gainus, Chris</creatorcontrib><creatorcontrib>Nash, Denis</creatorcontrib><title>Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>•mRNA VE against infection declined during periods of delta variant predominance.•High effectiveness of mRNA vaccines in 12–15 year old children in delta period.•Prior infection with pre-delta strains were as protective as full vaccination.•Hybrid immunity provides best protection against infection.•mRNA-1273 vaccine marginally more effective compared to BNT162b2 against infection.
It is critical to monitor changes in vaccine effectiveness against COVID-19 outcomes for various vaccine products in different population subgroups.
We conducted a retrospective study in patients ≥12 years who underwent testing for SARS-CoV-2 virus from April 14 through October 25, 2021, at urgent care centers in the New York metropolitan area. Patients self-reported vaccination status at the time of testing. We used a test-negative design to estimate vaccine effectiveness (VE) by comparing odds of a positive test for SARS-CoV-2 infection among vaccinated (n = 474,805), partially vaccinated (n = 87,834), and unvaccinated (n = 369,333) patients, adjusted for demographic factors and calendar time.
VE against symptomatic infection after 2 doses of mRNA vaccine was 96% (95% Confidence Interval: 95%, 97%) in the pre-delta period and reduced to 79% (95% CI: 77%, 81%) in the delta period. In the delta period, VE for 12–15-year-olds (85%; [95% CI: 81%, 88%]) was higher compared to older age groups (<65% for all other age groups). VE estimates did not differ by sex and race/ethnicity. VE against symptomatic infection was the highest for individuals with a prior infection followed by full vaccination. VE against symptomatic infection after the 2-dose mRNA-1273 vaccine (82% [95% CI: 80%, 84%]) was higher compared to the BNT162b2 vaccine (76% [95% CI: 74%, 78%]) in the delta period. VE after 1-dose of the Ad26.COV2.S vaccine was the lowest compared to other vaccines (19% [95% CI: 15%, 23%]) in the delta period.
VE against infection after two doses of the mRNA vaccines was high initially, but significantly reduced against the delta variant for both FDA-approved vaccines.</description><subject>2019-nCoV Vaccine mRNA-1273</subject><subject>Ad26COVS1</subject><subject>Age groups</subject><subject>Aged</subject><subject>Ambulatory Care</subject><subject>Antigens</subject><subject>Asymptomatic</subject><subject>BNT162 Vaccine</subject><subject>Confidence intervals</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 diagnostic tests</subject><subject>COVID-19 vaccine effectiveness</subject><subject>COVID-19 Vaccines</subject><subject>Disease</subject><subject>Effectiveness</subject><subject>Ethnicity</subject><subject>Humans</subject><subject>Infection-induced immunity</subject><subject>Infections</subject><subject>Metropolitan areas</subject><subject>Mortality</subject><subject>mRNA</subject><subject>mRNA vaccines</subject><subject>Patients</subject><subject>Retrospective Studies</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Subgroups</subject><subject>Test-negative design</subject><subject>Vaccine efficacy</subject><subject>Vaccine-induced immunity</subject><subject>Vaccines</subject><subject>Viral diseases</subject><issn>0264-410X</issn><issn>1873-2518</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU9v1DAQxS1ERbeFjwCyxKWXBP9LnFxA1aoFpEqVKCBultceL15t7MVOgvrt8bJLVbhwsmX_5s2beQi9pKSmhLZvNvWsjfEBakYYqymrCe-foAXtJK9YQ7unaEFYKypBybdTdJbzhhDScNo_Q6e8bbqOELlAP6-cAzP6GQLkjKPDyzh7W9EeH_Uz1mvtQx5xvh92Yxz06A3WwWL9-OHu8tNdtYxfK4Z9-C0ZQy7XQuIprSGM2OgEOMM4-rB-jk6c3mZ4cTzP0Zfrq8_LD9XN7fuPy8ubyoi-GauVFc4apoFr7fqGrWwZwLKeABGNlAaIk6TrBO-cdtY5K6kxknIhRAdtR_g5envQ3U2rAawpPpLeql3yg073Kmqv_v4J_rtax1n1suWMsiJwcRRI8ccEeVSDzwa2Wx0gTlkx2RIqWd_Lgr7-B93EKYUy3p6Sotjme0fNgTIp5pzAPZihRO2jVRt1XL3aR6soUyXaUvfq8SQPVX-yLMC7AwBln7OHpLLxEAxYn0oeykb_nxa_AM-uubQ</recordid><startdate>20230123</startdate><enddate>20230123</enddate><creator>Rane, Madhura S.</creator><creator>Robertson, McKaylee M.</creator><creator>Kulkarni, Sarah G.</creator><creator>Frogel, Daniel</creator><creator>Gainus, Chris</creator><creator>Nash, Denis</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230123</creationdate><title>Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting</title><author>Rane, Madhura S. ; Robertson, McKaylee M. ; Kulkarni, Sarah G. ; Frogel, Daniel ; Gainus, Chris ; Nash, Denis</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c495t-bd4fdc2ae3aaf952bd319d290e04577ce0f7088438fafdffd71cc7134448e6803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>2019-nCoV Vaccine mRNA-1273</topic><topic>Ad26COVS1</topic><topic>Age groups</topic><topic>Aged</topic><topic>Ambulatory Care</topic><topic>Antigens</topic><topic>Asymptomatic</topic><topic>BNT162 Vaccine</topic><topic>Confidence intervals</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 diagnostic tests</topic><topic>COVID-19 vaccine effectiveness</topic><topic>COVID-19 Vaccines</topic><topic>Disease</topic><topic>Effectiveness</topic><topic>Ethnicity</topic><topic>Humans</topic><topic>Infection-induced immunity</topic><topic>Infections</topic><topic>Metropolitan areas</topic><topic>Mortality</topic><topic>mRNA</topic><topic>mRNA vaccines</topic><topic>Patients</topic><topic>Retrospective Studies</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Subgroups</topic><topic>Test-negative design</topic><topic>Vaccine efficacy</topic><topic>Vaccine-induced immunity</topic><topic>Vaccines</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rane, Madhura S.</creatorcontrib><creatorcontrib>Robertson, McKaylee M.</creatorcontrib><creatorcontrib>Kulkarni, Sarah G.</creatorcontrib><creatorcontrib>Frogel, Daniel</creatorcontrib><creatorcontrib>Gainus, Chris</creatorcontrib><creatorcontrib>Nash, Denis</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rane, Madhura S.</au><au>Robertson, McKaylee M.</au><au>Kulkarni, Sarah G.</au><au>Frogel, Daniel</au><au>Gainus, Chris</au><au>Nash, Denis</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2023-01-23</date><risdate>2023</risdate><volume>41</volume><issue>4</issue><spage>989</spage><epage>998</epage><pages>989-998</pages><issn>0264-410X</issn><issn>1873-2518</issn><eissn>1873-2518</eissn><abstract>•mRNA VE against infection declined during periods of delta variant predominance.•High effectiveness of mRNA vaccines in 12–15 year old children in delta period.•Prior infection with pre-delta strains were as protective as full vaccination.•Hybrid immunity provides best protection against infection.•mRNA-1273 vaccine marginally more effective compared to BNT162b2 against infection.
It is critical to monitor changes in vaccine effectiveness against COVID-19 outcomes for various vaccine products in different population subgroups.
We conducted a retrospective study in patients ≥12 years who underwent testing for SARS-CoV-2 virus from April 14 through October 25, 2021, at urgent care centers in the New York metropolitan area. Patients self-reported vaccination status at the time of testing. We used a test-negative design to estimate vaccine effectiveness (VE) by comparing odds of a positive test for SARS-CoV-2 infection among vaccinated (n = 474,805), partially vaccinated (n = 87,834), and unvaccinated (n = 369,333) patients, adjusted for demographic factors and calendar time.
VE against symptomatic infection after 2 doses of mRNA vaccine was 96% (95% Confidence Interval: 95%, 97%) in the pre-delta period and reduced to 79% (95% CI: 77%, 81%) in the delta period. In the delta period, VE for 12–15-year-olds (85%; [95% CI: 81%, 88%]) was higher compared to older age groups (<65% for all other age groups). VE estimates did not differ by sex and race/ethnicity. VE against symptomatic infection was the highest for individuals with a prior infection followed by full vaccination. VE against symptomatic infection after the 2-dose mRNA-1273 vaccine (82% [95% CI: 80%, 84%]) was higher compared to the BNT162b2 vaccine (76% [95% CI: 74%, 78%]) in the delta period. VE after 1-dose of the Ad26.COV2.S vaccine was the lowest compared to other vaccines (19% [95% CI: 15%, 23%]) in the delta period.
VE against infection after two doses of the mRNA vaccines was high initially, but significantly reduced against the delta variant for both FDA-approved vaccines.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>36588007</pmid><doi>10.1016/j.vaccine.2022.12.039</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2023-01, Vol.41 (4), p.989-998 |
| issn | 0264-410X 1873-2518 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9763212 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | 2019-nCoV Vaccine mRNA-1273 Ad26COVS1 Age groups Aged Ambulatory Care Antigens Asymptomatic BNT162 Vaccine Confidence intervals Coronaviruses COVID-19 COVID-19 - prevention & control COVID-19 diagnostic tests COVID-19 vaccine effectiveness COVID-19 Vaccines Disease Effectiveness Ethnicity Humans Infection-induced immunity Infections Metropolitan areas Mortality mRNA mRNA vaccines Patients Retrospective Studies SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Subgroups Test-negative design Vaccine efficacy Vaccine-induced immunity Vaccines Viral diseases |
| title | Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T05%3A39%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20Covid-19%20vaccines%20against%20symptomatic%20and%20asymptomatic%20SARS-CoV-2%20infections%20in%20an%20urgent%20care%20setting&rft.jtitle=Vaccine&rft.au=Rane,%20Madhura%20S.&rft.date=2023-01-23&rft.volume=41&rft.issue=4&rft.spage=989&rft.epage=998&rft.pages=989-998&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2022.12.039&rft_dat=%3Cproquest_pubme%3E2760172997%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2767429030&rft_id=info:pmid/36588007&rft_els_id=S0264410X2201564X&rfr_iscdi=true |